Rocket Lab Gains 2.71 on 1.32B Volume 91st as Neutron Delay Overshadows Hypersonic Success

Market Snapshot

Rocket Lab (RKLB) closed Monday with a 2.71% gain, despite a 23.83% decline in trading volume to $1.32 billion, placing it 91st in volume rankings for the day. The stock’s performance contrasted with its technical indicators, which showed it trading 2.5% below its 20-day SMA and 5.0% below its 100-day SMA, signaling short-term weakness. The price action followed mixed analyst sentiment, with Cantor Fitzgerald raising its price target to $85.00 and Morgan Stanley upgrading to "overweight," while the Neutron rocket delay weighed on broader investor confidence.

Key Drivers

Neutron Rocket Delay Overshadows Q4 Earnings

Rocket Lab’s post-earnings slide was primarily driven by a significant delay in its Neutron rocket program. The first launch of the Neutron, initially scheduled for Q1 2026, was pushed to Q4 2026 due to a third-party manufacturing defect causing a Stage 1 tank rupture. Management downplayed direct financial impacts, but the setback created uncertainty around the rocket’s role in future revenue streams, particularly for government and commercial contracts. This delay overshadowed the company’s Q4 results, which included a revenue beat of $179.65 million and a narrower-than-expected loss of nine cents per share.

Hypersonic Test Mission Bolsters Strategic Credibility

A counterbalancing positive was the successful hypersonic test mission for the U.S. Defense Innovation Unit (DIU) on February 27. The mission, part of Rocket Lab’s HASTE vehicle series, marked its second such test in three months and the seventh HASTE flight, maintaining a 100% success rate. The test deployed a scramjet-powered aircraft at hypersonic speeds, underscoring Rocket Lab’s role in advancing U.S. defense technology. This achievement reinforced the company’s strategic value to government partners and highlighted its technical capabilities, potentially offsetting some of the Neutron-related pessimism.

Analyst Upgrades and Mixed Technical Indicators

Analyst activity provided a near-term tailwind, with Cantor Fitzgerald raising its price target to $85.00 and Morgan Stanley upgrading to "overweight" with a $105.00 target. The stock carries a "Moderate Buy" consensus rating, with an average price target of $75.92. However, technical indicators painted a mixed picture: the RSI at 50.00 indicated neutrality, while the MACD (0.10) remained below its signal line (0.15), suggesting bearish pressure. The stock is currently closer to its 52-week high than low, reflecting a broader upward trend despite recent volatility.

Upcoming Earnings and Insider Sales

The next major catalyst for Rocket LabRKLB+2.71% will be its May 7, 2026, earnings report, where analysts expect a narrowed loss of nine cents per share and revenue of $188.54 million. Additionally, insider sales by CEO Peter Beck and Director Nina Armagno in December raised questions about management’s confidence, though these transactions did not directly impact the stock’s recent performance. The combination of delayed product milestones, technical indicators, and analyst optimism creates a complex landscape for investors ahead of the next earnings cycle.